David M. DeMedio
Nessuna posizione attualmente
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| George Harrum | M | - | 23 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| George Raymond Jensen | M | 75 | 19 anni | |
| Steven Katz | M | 76 |
Gammacan International, Inc.
 Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 11 anni |
| Limor Zur-Stoller | F | 55 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | - |
| Denis Kouznetsov | M | - | 16 anni | |
| Bradley Tirpak | M | 54 | 4 anni | |
| Jack Edward Price | M | 78 | - | |
| William J. Reilly | M | 76 | 8 anni | |
| Frank A. Petito | M | 56 | 2 anni | |
| Steve G. Illes | M | - | - | |
| Albert Passner | M | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 2 anni |
| Deborah G. Arnold | F | 73 | 3 anni | |
| William J. Schoch | M | 59 | 8 anni | |
| Joel P. Brooks | M | 65 | 13 anni | |
| Maeve McKenna Duska | F | 49 | 16 anni | |
| Bruce R. Shirey | M | - | - | |
| Cary M. Sagady | M | - | - | |
| Veronica Rosa | F | - | - | |
| Mary West Young | F | 68 | - | |
| Stephen W. McHugh | M | 66 | 3 anni | |
| Chaime Orlev | M | 53 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 3 anni |
| John McLaughlin | M | - | 5 anni | |
| James D. Smith | M | 65 | 1 anni | |
| Peter A. Michel | M | 81 | 1 anni | |
| Yair Aloni | M | 74 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | - |
| Shmuel Levi | M | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | - |
| William L. van Alen | M | 89 | 17 anni | |
| Scott Nissenbaum | M | - | 1 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 24 | 85.71% |
| Israele | 6 | 21.43% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- David M. DeMedio
- Contatti personali
